- Home
- FFAI vs CTNM Comparison
FFAI vs CTNM Comparison
Compare FFAI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFAI
- CTNM
- Stock Information
- Founded
- FFAI 2014
- CTNM 2009
- Country
- FFAI United States
- CTNM United States
- Employees
- FFAI N/A
- CTNM N/A
- Industry
- FFAI
- CTNM
- Sector
- FFAI
- CTNM
- Exchange
- FFAI NYSE
- CTNM Nasdaq
- Market Cap
- FFAI 111.5M
- CTNM 122.9M
- IPO Year
- FFAI N/A
- CTNM 2024
- Fundamental
- Price
- FFAI $1.75
- CTNM $3.92
- Analyst Decision
- FFAI
- CTNM Strong Buy
- Analyst Count
- FFAI 0
- CTNM 4
- Target Price
- FFAI N/A
- CTNM $22.50
- AVG Volume (30 Days)
- FFAI 12.2M
- CTNM 218.6K
- Earning Date
- FFAI 08-13-2025
- CTNM 08-12-2025
- Dividend Yield
- FFAI N/A
- CTNM N/A
- EPS Growth
- FFAI N/A
- CTNM N/A
- EPS
- FFAI N/A
- CTNM N/A
- Revenue
- FFAI $853,000.00
- CTNM N/A
- Revenue This Year
- FFAI $115,335.99
- CTNM N/A
- Revenue Next Year
- FFAI N/A
- CTNM N/A
- P/E Ratio
- FFAI N/A
- CTNM N/A
- Revenue Growth
- FFAI 8.52
- CTNM N/A
- 52 Week Low
- FFAI $0.83
- CTNM $3.35
- 52 Week High
- FFAI $21.89
- CTNM $21.92
- Technical
- Relative Strength Index (RSI)
- FFAI N/A
- CTNM N/A
- Support Level
- FFAI N/A
- CTNM N/A
- Resistance Level
- FFAI N/A
- CTNM N/A
- Average True Range (ATR)
- FFAI 0.00
- CTNM 0.00
- MACD
- FFAI 0.00
- CTNM 0.00
- Stochastic Oscillator
- FFAI 0.00
- CTNM 0.00
About FFAI FARADAY FUTURE INTELLIGENT ELEC INC
Faraday Future Intelligent Electric Inc is a shared intelligent mobility ecosystem. The company is poised to break the boundaries between the Internet, IT, creative, and auto industries with product and service offerings that integrate new energy, AI, Internet, and sharing models. The company has additional engineering, sales, and operational capabilities in China and plans to develop its manufacturing capability in China through a joint venture.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.